RecruitingNCT06970288
Effectiveness of Introducing Ultra-High B-Value Diffusion-Weighted Imaging as a Modified Abbreviated Protocol for Breast Cancer Detection
Sponsor
Ain Shams University
Enrollment
85 participants
Start Date
May 10, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.
Eligibility
Sex: FEMALEMin Age: 30 YearsMax Age: 50 Years
Inclusion Criteria4
- • Women with suspicious breast mass (BIRADS 4a)
- High risk women (Positive family history)
- Women with suspicious axillary lymph nodes by Ultrasound
- Women with dense breasts coming for MRI imaging.
Exclusion Criteria7
- • Contraindications to MRI
- Pacemaker, cochlear implant, claustrophobia, ocular implants
- Contraindications to contrast administration:
- Elevated kidney functions
- Women who haven't undergone reliable Mammogram \& Ultrasound
- Women with prior treatment or intervention (e.g. biopsy)
- Patients' refusal.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06970288
Related Trials
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT059415204 locations
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT0618475011 locations
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT061953063 locations